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CASE PRESENTATIONS
Patient 1
A 53-year-old man lost a kidney 35 years ago after an
accident. Hypertension was detected 18 years ago, but
he declined treatment. Last year he presented to the
Aachen University Hospital with end-stage renal disease
(ESRD), presumably due to hypertensive renal dam-
age. Ambulatory peritoneal dialysis (PD) was started. In
view of recurrent compliance problems, including skip-
ping of PD exchanges, a transfer to hemodialysis (HD)
was planned, which he refused. Finally, he was admitted
again with uremic gastritis, pericardial effusion, polyneu-
ropathy, and a urinary tract infection. The PD dose was
increased, appropriate therapy for his medical problems
was initiated, and his condition improved. Despite these
measures, his serum phosphate rose from usual levels of
2.5 to 3.0 mmol/L to a maximum of 4.8 mmol/L. The
serum calcium remained normal. He admitted dietary
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phosphate excesses and having skipped his phosphate
binders (sevelamer plus calcium acetate), claiming that
the pills were too big to swallow. Within 3 days he de-
veloped an abscess-like yet painless lesion on his thumb
(Fig. 1A), which was identified as a calcification on ra-
diograph (Fig. 1B). A bone scintigraphy (Fig. 2), chest
(Fig. 3A), and cranial CT (Fig. 3B), as well as an ophthal-
mologic examination (Fig. 4) confirmed widespread ex-
traosseous calcifications, involving but not limited to the
lungs, pericardium, large arteries, abdominal wall, and
conjunctiva. Serum fetuin-A was 0.33 g/L (normal range
0.5 to 1.0 g/L), and his IC50 calcium-phosphate precipi-
tation inhibitory activity in serum was 10.2 lL (normal
IC50 6.4 ± 2.6 lL).
Patient 2
A 64-year-old woman weighing 48 kg has under-
gone chronic HD in a private dialysis center for the
past 17 years. She had ESRD due to tubulointersti-
tial nephropathy. She underwent surgery for tertiary
hyperparathyroidism 7 years ago, and had reimplanta-
tion of one gland. Secondary hyperparathyroidism re-
curred; the iPTH serum levels ranged between 133 and
632 ng/L (mean 308 ng/L) over the past 6 years. Over
the last 5 years, no episodes of hypercalcemia (that is,
serum calcium >2.55 mmol/L) had been documented,
and her serum phosphate had been well controlled with
low doses of an aluminum-containing phosphate binder
(mean serum phosphate over the previous 5 years was
1.36 ± 0.39 mmol/L; range, 0.7 to 2.57 mmol/L; N = 63).
Last year, she was admitted to the Aachen University
Hospital because of unstable angina. Angiography re-
vealed diffuse coronary artery disease without options
for interventional measures. Radiographic and CT eval-
uations documented extensive mitral valve ring calcifica-
tions, pericardial calcifications, and widespread vascular
disease, including coronary calcification. C-reactive pro-
tein was chronically elevated, with a mean of 31 mg/L
(range 28 to 38 mg/L). Serum fetuin-A was 0.38 g/L, and
her IC50 calcium-phosphate precipitation inhibitory ac-
tivity in serum was 13.6 lL.
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Fig. 1. Photograph of right thumb of Patient 1 (A). At first glance, the tumorous calcification resembles a small abscess. (B) Radiograph demonstrates
the typical cloudy appearance of the extraosseous calcification (arrowheads) with interwoven fibrous tissue.
DISCUSSION
DR. JU¨RGEN FLOEGE (Professor of Medicine, Direc-
tor, Renal Division, University Hospital, Aachen, Ger-
many): These two patients provide important insights
into the pathogenesis of uremic extraosseous calcifica-
tion. Whereas Patient 1 is apparently a case of noncom-
pliance and “metastatic” calcification, why does Patient 2
have such extensive calcification? She is not particularly
old, not diabetic, ate little, and consequently had a low
phosphate intake, was compliant with her medication,
had not received calcium-containing phosphate binders
over recent years, and had never had a markedly elevated
calcium-phosphate product.
Before embarking on this discussion, three points need
to be clear: (1) I will attempt to avoid mixing data ob-
tained in patients with ESRD with data from patients
with normal renal function, as the pathogenetic principles
overlap only in part. Also, insights into cardiovascular
disease gained in one group can be completely different
in the other, a phenomenon termed “reverse epidemiol-
ogy” [1]. (2) For didactic purposes, I will discuss vascular,
valvular, organ, and soft tissue calcifications together, re-
alizing that they may have different origins. However,
in most cases, currently available information is too lim-
ited to distinguish different pathogenetic pathways. (3)
Again, for didactic purposes and largely because of a lack
of available data, I will use the global term “calcification”
for extraosseous mineralization, realizing that important
histologic and chemical subsets of calcification exist.
Calcification in patients with ESRD can produce a
range of pathologies, including calcific uremic arteri-
olopathy (formerly termed “calciphylaxis”; not covered
in this review) [2], extraosseous soft tissue (Fig. 5) and
solid organ calcification, corneal and conjunctival calcifi-
cation, peritoneal calcification, and vascular and valvular
calcification [3–7]. Nephrologists have been plagued by
these complications from the early days of dialysis [3–5,
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Fig. 2. Bone scintigraphic image of Patient
1 following the injection of 570 MBq 99mTc-
HDP. Note extensive calcification of the lungs
(arrows), right thumb (arrow), upper sternum,
thyroid region, and base of the skull.
7, 8]. For example, data obtained in 120 uremic children
between 1960 and 1983 revealed soft tissue calcification
in 60%, most frequently involving blood vessels, lung,
kidney, myocardium, central nervous system, and gas-
tric mucosa [3]. Autopsy findings in the 1970s confirmed
soft tissue, including vascular, calcification in 50% to 80%
of HD patients [5, 6]. Thus, extraosseous calcification is
neither a new nor a dramatically increasing problem in
uremic patients. The latter impression may exist because
new, non-invasive techniques have increased our ability
to detect calcifications.
Morphologic and biochemical features
Vascular calcification involves large- and medium-
sized arteries, whereas veins virtually never calcify unless
placed into the arterial system. In rare cases, vascular
prostheses also calcify. Intimal calcification only occurs
within inflammatory atherosclerotic plaques, whereas in
mediasclerosis (Mo¨nckeberg sclerosis) muscular arteries
undergo noninflammatory medial calcification. In medi-
asclerosis, elastic laminae chiefly in the inner two-thirds
of the media calcify around fractured disorganized elastin
fibers [9, 10], and formation of bone-like trabecular struc-
tures results. Glycoxidative modification of elastin in ure-
mia might contribute to this process [11]. Mediasclerosis
commonly occurs with normal aging, but it is markedly
aggravated in uremia [6, 12] and diabetes mellitus [12],
conditions associated with accelerated aging of various
tissues [10].
The arterial tree has considerable variability in the sus-
ceptibility and the type of calcification. In older HD pa-
tients, calcification in the aortic wall and radial artery
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Fig. 3A. Chest CT image of Patient 1. Note the large pericardial calcifications (arrows) as well as calcification of the descending aorta (arrowhead).
consistently involves both the intima and media, whereas
in younger dialysis patients, isolated mediasclerosis pre-
dominates [11, 13]. However, at least in the iliac artery, in-
timal lesions with microcalcifications have been described
even in uremic children [14]. Vascular calcification is not
a random process in chronic HD patients. For example,
calcification of the internal thoracic or hepatic arteries is
unusual [15, 16].
Valvular calcifications often start at the site of valve
insertion, in particular the mitral annulus, and then ex-
tend in the direction of the cusps. Commissural fusion
and stenosis, particularly of the aortic valve, develop in
advanced stages [4, 7]. Compared with nonrenal disease
populations, patients with ESRD are much more likely to
have basal mitral leaflet calcification and papillary mus-
cle calcification; also, calcification of intervalvular fibrosa
and of the tricuspid annulus is noted only in ESRD pa-
tients [17].
In cases of uremic tumor-like calcinosis, the most com-
mon sites are the elbows, hips, hands, and wrists [18]. The
calcium deposits are typically multiple, para-articular, la-
bile, and have a fluid-viscous consistency [19]. “Active”
lesions, that is, calcification centers surrounded by
mononuclear or multinuclear macrophages, osteoclast-
like giant cells, fibroblasts, and chronic inflammatory el-
ements, can be distinguished from “inactive” lesions, in
which calcified material is surrounded by fibrous tissue
(Fig. 5).
Extraosseous calcifications in uremic patients can vary
in chemical composition, even within the same site. Soft
tissue and vascular calcifications in uremic patients can
contain amorphous calcium phosphate or hydroxyap-
atite (Ca5(PO4)3OH), that is, the same form of calcium
crystals as in bone [8, 20, 21]. Another form of calcium
(magnesium) phosphate, whitlockite (CaMg3)(PO4)2,
has been reported in the elastic laminae in the media
of non-uremic human aorta [9] as well as in uremic vis-
ceral organs [8]. Finally, brushites (CaHPO4·2H2O) were
found solely in stenotic arteriovenous fistulas of patients
undergoing HD [22]. Calcium oxalate crystals, unless
associated with primary oxalosis, are not detected in the
uremic vasculature [20].
Detection and quantification
The calcification pattern in large arteries as seen on
conventional radiographs, patchy, irregular versus lin-
ear, “tramline”-like deposits, allows a crude distinction
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Fig. 3B. Cranial CT image of Patient 1 demonstrating massive vascular calcification of the medial and anterior cerebral arteries.
between atherosclerotic intimal and medial vascular cal-
cification [23]. But ultrasound, intravascular ultrasound,
and optical coherence tomography can provide bet-
ter differentiation of vascular calcification types. Other
techniques employed for detecting vascular or other
calcifications include echocardiography, digital subtrac-
tion angiography, magnetic resonance tomography, and
bone scintigraphy [7, 24] (Fig. 2). The two most widely
used methods for detecting vascular, and particularly
coronary, calcifications are electron-beam computed to-
mography (EBCT) and multi-row helical computerized
tomography (CT) [25–27]. Multi-row helical CT offers
better signal-to-noise ratio and higher spatial resolution,
whereas EBCT offers better temporal resolution and
fewer cardiac motion artefacts [28]. Semi-quantitative as-
sessments can be performed using the Agatston score
(the product of plaque area and a density factor), total
calcium volume, or a calcium mass score [28]. Neither CT
method, however, can distinguish between calcifications
of the vascular intima and media.
Clinical consequences
In contrast to atherosclerotic intimasclerosis, medi-
asclerosis is generally nonocclusive. Mediasclerosis re-
duces the dampening ability of blood vessels and thus
induces pseudohypertension and increased pulse wave
velocity [29]. Through these mechanisms waves return
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Fig. 4. Conjunctival calcifications in Patient 1.
more quickly from the periphery, further augmenting the
systolic wave and lowering diastolic pressure. The resul-
tant higher pulse pressure, like aortic stiffness and pulse
wave velocity, is associated with a higher mortality rate
in ESRD patients [29–31]. By increasing left-ventricular
afterload, a high aortic pulse wave velocity is also asso-
ciated with left-ventricular hypertrophy [29]. Similarly,
valvular and cardiac calcifications are associated with the
development of left-ventricular hypertrophy, heart fail-
ure, coronary ischemia, arrhythmias, valvular stenosis, in-
creased risk of infective endocarditis, and, in rare cases,
thromboses with emboli [4, 5, 7, 24, 32].
The degree of vascular or valvular calcification in HD
patients correlates with the severity of cardiovascular
disease as determined clinically, and predicts cardiovas-
cular and all-cause mortality [23, 29, 33, 34]. Whether
the presence of coronary calcifications in uremic patients
has a similar high predictive value for future cardiac
events, as in the general population, where it predicts
total atherosclerotic plaque burden [35], is unknown.
Soft tissue “metastatic” calcifications in dialysis pa-
tients are typically multiple, painless, large, and can be-
come symptomatic with nerve compression and impair-
ment of joint mobility [18] (Fig. 5). Rare consequences of
calcifications include vasculopathic proximal myopathy,
penile necrosis, rupture of calcified tendons, respiratory
failure, breast pain due to calcification of mammary ves-
sels, headache due to dural calcification, and symptoms
related to spinal compression.
Risk factors
Age and time on dialysis are central determinants of
extraosseous and, in particular, vascular and valvular cal-
cifications (Table 1), but even pediatric dialysis patients
are not spared [3, 5, 14, 24, 25, 27, 34, 36, 37]. The de-
velopment of calcifications can progress very rapidly, and
calcification scores both in vessels and valves can increase
by 20% to 30% within only one year [25, 38].
Various other risk factors for vascular and valvular
calcifications have been identified (Table 1). Dialysis
patients with a predominantly intimal calcification pat-
tern in the pelvic vessels were older and characterized
by the presence of “typical” cardiovascular risk factors
(for example, smoking, dyslipidemia); patients with me-
dial calcifications were younger and characterized by a
longer duration of HD treatment and derangements of
the calcium and phosphate balance [23]. A consistent risk
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Fig. 5A. Teutschla¨nder disease. Massive tumor-like calcification in the region of the left shoulder of a 50-year-old patient on chronic HD who
refused phosphate binders.
factor is diabetes mellitus. This finding is not unexpected
given that both atherosclerosis and mediasclerosis are as-
sociated with diabetes even in the absence of uremia.
Furthermore, several studies noted that in patients with
ESRD, the calcification risk increases in the presence of
hypercalcemia, hyperphosphatemia, and/or with the use
of calcium-containing phosphate binders [3, 7, 23, 27, 33,
34, 36, 38, 39]. Other studies found no such association
[16, 25]. This contrast might relate to sample sizes, but in
particular to the difficulty of relating a long-term event
such as calcification to rapidly fluctuating serum parame-
ters. Similarly, few studies [34, 36], but not the majority [5,
16, 25, 27], detected an association between calcification
and parathyroid hormone (PTH) levels, or parathyroid or
bone morphology. A direct role of PTH is also question-
able, given that pronounced vascular calcification or even
uremic calcific arteriolopathy can occur in the absence of
hyperparathyroidism and that oversuppression of PTH,
which results in adynamic bone disease, is associated with
an increased risk of calcification [40, 41].
Tumorous soft-tissue calcifications (Teutschla¨nder dis-
ease) usually develop in the context of long-standing
pronounced hyperparathyroidism and/or excessive hy-
perphosphatemia (Figs. 1 and 5). Again, the role of
PTH itself is questionable, since tumor-like calcifications
can regress despite progressive hyperparathyroidism
[42].
Several other risk factors for cardiovascular calcifi-
cation are noteworthy. A number of studies noted an
association between calcification and the malnutrition,
inflammation, and atherosclerosis (MIA) syndrome, and
with serum parameters related to it [27, 34, 36, 43]. Dys-
lipidemia was associated with more rapid progression of
uremic vascular/valvular calcification in one small study
[44] but not in others [33, 34], and another small study
even noted lower total LDL and HDL cholesterol, as
well as lower triglycerides in the presence of coronary
calcifications [45]. The role of systemic acidosis or alka-
losis in promoting uremic extraosseous calcification is not
known.
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Fig. 5B, C. Intraoperative aspect, showing large nodules of whitish material (B). Histologic examination disclosed 2 calcified areas (C) of different
morphology separated by a fibrous septum (F). Whereas the left calcified area shows larger crystals and more cellular reaction, including osteoclast-
like cells (insert), the right calcified zone evokes relatively little cellular response (PAS stain, magnification ×50; with insert ×200; specimen kindly
provided by R. Knu¨chel-Clarke, Dept. of Pathology, University Hospital Aachen) (C).
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Table 1. Factors promoting or inhibiting extraosseous calcification in vitro and in vivo
Effect on calcification References
Promoting factors
Age of patient ↑(epidemiologic studies) 25, 27, 33, 34, 37, 43, 94
Duration of dialysis ↑(epidemiologic studies) 27, 33, 36, 37, 43
Inorganic phosphate and/or Ca ×
PO4 product
↑(VSMCa in vitro; klotho-deficient mice;
epidemiologic studies)
3, 7, 23, 27, 33, 34, 38, 39, 47–49, 58
Oral Ca2+−containing PO4−
binder dose
↑(epidemiologic studies) 27, 38
Vitamin D3 ↑(VSMC in vitro and epidemiologic data) 37, 59, 95
Diabetes, AGEs ↑(microvascular pericytes in vitro; mouse
model; in vivo association in HD patients;
epidemiologic studies)
33, 34, 60, 61, 94, 96
Increased serum fibrinogen or
CRP or low albumin
↑(epidemiologic studies) 34, 36, 43
Inflammatory cytokines ↑(VSMC in vitro) 58
Modified low-density lipoprotein
(LDL)
↑(VSMC in vitro) 55, 95
Hyperhomocysteinemia ↑(epidemiologic studies) 36, 43, 94
Estrogen ↑(VSMC in vitro) 97
Dexamethasone ↑(VSMC in vitro) 98
Leptin ↑(VSMC in vitro) 62
Genetic factors ↑(human in vivo data) 63, 64
Inhibitory factors
Magnesium ions ↓(in vitro; in vivo association in PD patients) 21, 54
High-density lipoprotein (HDL) ↓(VSMC in vitro) 56
PTHrP ↓(VSMC in vitro) 65
Osteoprotegerin ↓(in vitro data, knockout mice, rat model,
human in vivo data)
39, 66
Osteopontin ↓(in vitro and in vivo murine data) 68, 69
BMP-7 ↓(uremic mice) 67
Inorganic pyrophosphate ↓(in vivo human data) 74, 99
Matrix GLA protein ↓(knockout mice) 70
Fetuin-A ↓(in vitro data, knockout mice, human in vivo
data)
26, 79, 80, 82
aVSMC, vascular smooth muscle cells.
Pathogenesis
Although cardiovascular calcifications occur in the
presence of normal renal function, even a moder-
ate decrease in the glomerular filtration rate (GFR)
dramatically augments their prevalence [12]. Also,
atherosclerotic plaques in uremia calcify much earlier and
more heavily [20].
Elevated serum phosphate levels are a potent pre-
dictor of cardiovascular events in patients with ESRD
[46]. The most attractive explanation for these findings
is a pathogenetic link among high serum phosphate lev-
els, cardiovascular calcification, and increased mortality
rates. In mice, hyperphosphatemia, even in the absence
of renal failure, is associated with vascular calcifications
[47]. Human aortic vascular smooth muscle cells (VSMC)
cultured in a solution containing 2.0 mmol/L phosphate
formed bioapatite but did not in a 1.4 mmol/L phosphate
solution [48]. Bioapatite formation was inhibited when
VSMC phosphate uptake was blocked with an antagonist
of the sodium-phosphate co-transporter [48, 49]. This is
perhaps the most convincing evidence that calcium and
phosphate precipitation, at least in the vessel wall, is likely
an active cellular rather than a passive “metastatic” pro-
cess. In VSMC, increased intracellular phosphate down-
regulates typical VSMC genes and contributes to various
osteoblast-like phenotype changes, including the forma-
tion of matrix vesicles, the expression of core binding
factor 1 (Cbfa-1, a central transcription factor in os-
teogenic differentiation), the expression of alkaline phos-
phatase, the production of calcium-binding proteins such
as osteocalcin and osteopontin, and the laying down of a
collagen-rich extracellular matrix [48, 50]. However, the
origin of these osteoblast-like, “calcifying vascular cells”
in vivo is not fully clarified [51]. In vivo Cbfa-1, alkaline
phosphatase, and osteopontin are present in uremic cal-
cified arteries and calcific arteriolopathy [13, 40, 52]. In
plasma of HD patients, osteopontin correlated with the
extent of vascular calcifications [53].
It is currently unknown whether these processes are
similarly operative in uremic intimal and medial calcifi-
cation and how they relate to soft tissue calcifications.
Also, none of this information excludes the existence
of true “metastatic” calcification, that is, passive pre-
cipitation, in instances of an excessive calcium × phos-
phate product. In fact, today’s first patient is probably
good evidence for the existence and pathogenetic rele-
vance of this process. In light of today’s knowledge, it
is certainly correct to place the main pathogenetic and
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therapeutic emphasis on phosphate, but other factors
present in uremia also affect the development of calci-
fications [52].
While the role of calcium, in particular hypercalcemia,
in promoting extraosseous calcifications is obvious and
evidenced by several epidemiologic studies (Table 1),
magnesium might inhibit calcification. In vitro and in vivo,
the presence of Mg2+ ions reduces the crystallite size of
apatite [21], and at least one study related higher serum
magnesium levels in ESRD patients to a lower progress
of arterial calcifications [54].
Blood lipids also can modulate calcification. In vitro,
modified LDL increased, while HDL inhibited VSMC
calcification [55, 56]. In non-ESRD patients, reducing to-
tal cholesterol slowed the progression of coronary artery
calcification [57], but evidence for a role of lipids in ure-
mic calcification is less clear. As I said a moment ago, epi-
demiologic studies on the association of dyslipidemia and
uremic calcification are contradictory, and low choles-
terol can even predict cardiovascular mortality in ESRD
patients [1].
A role of inflammation in promoting uremic calcifica-
tions receives better support from epidemiologic stud-
ies (Table 1). In vitro, macrophage-derived TNF-a and
oncostatin-M induce calcification in VSMC [58]. Further-
more, inflammation can contribute to the inverse cor-
relation between calcification scores and bone mineral
densities in dialysis patients [25]. Finally, links have been
established in vitro and in vivo with a number of other
potential modulators of calcification in ESRD (Table 1),
including calcitriol [37, 59], HbA1c levels [60], advanced
glycation end products [61], leptin [62], and some genetic
factors [63, 64].
What agents inhibit calcification? Extracellular fluids
are supersaturated with calcium and phosphate so ex-
traosseous calcification must usually be prevented by
inhibitors.
Various factors decrease the rate of calcification or
even reverse established calcifications, including parathy-
roid hormone–related peptide [65], osteoprotegerin [39,
66], bone morphogenic protein (BMP)-7 [67], and osteo-
pontin [68, 69] (Table 1). The relevance of most of these
various factors to human uremic calcification in vivo is
currently unknown.
The local inhibitor matrix GLA protein (MGP) is a
gamma-carboxylated mineral-binding extracellular ma-
trix protein, expressed by VSMC. MGP knockout mice
develop severe cartilage and arterial medial calcifications
[70]. Also, MGP has been found in human atherosclerotic
plaques surrounding calcifications [71, 72]. In humans,
mutations of MGP leading to a nonfunctional protein re-
sult in calcification of cartilage and vessels [73]. Vitamin
K deficiency predisposes to undercarboxylated, inactive
MGP, which might explain why warfarin therapy is a risk
factor for calcific uremic arteriolopathy [2]. Another re-
cently identified inhibitor of vascular calcification is in-
organic pyrophosphate, which is generated by a cell sur-
face enzyme of VSMC. Inactivating mutations of the cell
surface enzyme result in calcification of muscular arter-
ies [74]. Studies in the mid-1970s linked increased bone
pyrophosphate content to osteopenia and pulmonary cal-
cifications in HD patients [75].
Systemic, circulating inhibitors also contribute to the
prevention of calcium deposits. Fetuin-A, or alpha-
2-Heremans-Schmid glycoprotein, is synthesized by
hepatocytes, exists in the extracellular space in high
concentrations (0.5 to 1.0 g/L), and is downregulated
during episodes of inflammation. Fetuin-A exhibits anti-
inflammatory activity [76] and increases phagocytosis of
apoptotic bodies [77]. The latter activity might be im-
portant in preventing vascular calcification [78]. In vitro,
fetuin-A is a highly potent inhibitor of hydroxyapatite
formation [79]. Fetuin-A is responsible for about one-half
the precipitation inhibitory effect of serum [80] by form-
ing in serum a high-molecular-mass complex of calcium
phosphate mineral, fetuin-A, as well as traces of MGP
and secreted phosphoprotein 24 [81]. In fetuin-A knock-
out mice, most soft tissues became severely calcified
[82].
In HD patients, serum fetuin-A levels correlate nega-
tively with C-reactive protein (CRP) levels and are sig-
nificantly lower when compared to controls with normal
renal function [26]. Also, uremic sera were less efficient at
inhibiting calcium phosphate crystal formation than were
normal sera. That is, they exhibited higher IC50, and this
effect was reversed by the addition of fetuin-A [26]. In
particular, the second patient is a good example of the ef-
fects of chronic fetuin-A downregulation in the course of
MIA syndrome. We observed extremely low serum levels
in HD patients with calcific uremic arteriolopathy, thus
offering evidence supporting the role of reduced fetuin-
A levels in inflammation [82]. Finally, in HD patients,
low fetuin-A is an independent predictor of all-cause and
cardiovascular mortality [26].
What determines the localization of calcifications? In
atherosclerotic intimal vascular calcification as well as in
mediasclerosis, it is assumed that membrane vesicles de-
rived from apoptotic cells and/or spatially restricted cal-
cium release serve as the nidus for calcium precipitation
[78]. Such local cellular disturbances, probably combined
with alterations of the extracellular matrix, likely are cen-
tral determinants of the localization of calcium deposits.
Therapeutic approaches
Established calcifications are difficult to treat. For ex-
ample, after valve surgery, calcifications can recur rapidly
[4]. Even successful renal transplantation does not al-
ways halt the progress of vascular calcifications. However,
in individual cases, marked clinical improvement and
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regression of extraosseous calcification have followed an
increase in the dialysis dose, parathyroidectomy, opti-
mization of the calcium × phosphate product, therapy
with a bisphosphonate, therapy of aluminum overload, or
successful renal transplantation [42, 83–86]. Large symp-
tomatic tumorous calcinosis occasionally requires surgi-
cal intervention [18].
Existing options for preventing calcification include
an optimization of dialysis dose, for example, initiat-
ing nightly HD or short-duration HD 6 days per week,
parathyroidectomy if indicated, modifying calcium load,
and the use of phosphate binders [87]. A single study
also noted a slower progression or even regression of
peripheral arterial calcifications, as detected on plain ra-
diographs, in ESRD patients with high serum magnesium
levels [54]. Sevelamer, a phosphate-binding polymer, sup-
presses ectopic calcifications in uremic rats [88]. In a
clinical study, sevelamer slowed the progression of cal-
cifications in coronary arteries and in the aorta, although
whether these effects relate to sevelamer’s phosphate-
binding or lipid-lowering properties remains unclear [38].
The possible etiologic mechanisms should lead to the
development of novel approaches for treating and pre-
venting calcification in dialysis patients. Vitamin D ana-
logues [89], calcimimetics [90], and bisphosphonates [91]
might provide alternative ways of modifying calcium and
phosphate levels, that is, producing a lower calcium ×
phosphate product; control of lipid levels with statins or
bile acid sequestrants as well as therapy with calcium
antagonists also could have beneficial effects [57, 92].
Possible anti-inflammatory strategies could include us-
ing pyrogen-free dialysate, which can increase fetuin-A
serum levels [abstract; Westenfeld R et al, Nephrol Dial
Transplant 18(Suppl 4):701–702, 2003] and therapies that
reduce cytokine levels. Finally, after we gain a better un-
derstanding of their regulatory elements, we could stimu-
late synthesis of inhibitors of calcification such as fetuin-A
or use them as therapeutic agents.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Division of Nephrol-
ogy, Tufts-New England Medical Center, Boston, Mas-
sachusetts): You mentioned that inflammatory agents
such as TNF-a might be involved in calcification. Has
your precipitation inhibition test for calcification deter-
mined whether one of the newer anti-TNF agents, such as
those used in rheumatoid arthritis, is effective? Second,
given that calcification can occur in alkaline tissue, what
is the role of pH?
DR. FLOEGE: The efficacy of anti-TNF therapy is un-
proven but likely because in rheumatoid arthritis anti-
TNF therapy quickly lowers C-reactive protein levels and
thereby presumably increases fetuin-A levels. We are just
starting a study that will answer this latter question. I am
not aware of anybody who has studied anti-TNF ther-
apy in dialysis patients. It might make sense for us to
treat, for example, our second patient, who has persis-
tently high CRP levels, with anti-TNF agents. Now let
me address your second question. Despite much specu-
lation on the role of acid-base status in calcification, we
have no data on it. In fact, pH is a potential confounder in
many studies that have looked at calcification in dialysis
patients. Looking at pH in dialysis patients is at best dif-
ficult because systemic pH is almost never stable and you
would have to determine a weekly averaged pH to take
into account bicarbonate loading, redistribution, dietary
effects, etc.
DR. MARKUS KETTELER (Assistant Professor, Division
of Nephrology, University of Aachen, Germany): What
would you recommend as treatment for uremic calcific
arteriolopathy?
DR. FLOEGE: If uremic calcific arteriolopathy is medi-
ated, at least in part, through excessive lowering of fetuin-
A, it might make sense to administer fetuin. While it is
difficult to conceive that this can be achieved using re-
combinant fetuin, given its high serum levels, plasma is
an excellent source. One can speculate whether the ad-
ministration of fresh frozen plasma or even plasma ex-
change might be helpful in uremic calcific arteriolopathy.
Interestingly, there are now some first clinical observa-
tions that corticosteroids are helpful in this situation [2],
and one of the effects of corticosteroids is an increase
in fetuin-A synthesis (Jahnen-Dechent W, personal com-
munication). Of course, in the situation of uremic calcific
arteriolopathy, using corticosteroids can be problematic,
as patients usually die from infection. The administration
of plasma therefore might be a safer approach. To my
knowledge, this has not been tested.
DR. TILMAN DRU¨EKE (INSERM, Research Director
and Associate Professor of Nephrology, Necker Hospital,
Paris, France): With regard to John Harrington’s ques-
tion on the role of acid-base status, it has been known
for several years from studies by his former fellow David
Bushinsky [93] and others that chronic acidosis increases
the release of calcium and phosphate from bone, and this
alteration might contribute to soft tissue calcification. On
the other hand, we know that alkalosis favors the precip-
itation of phosphate. This could explain how, in the pres-
ence of systemic acidosis, local alkalotic conditions could
favor the development of calcifications.
DR. FLOEGE: Your comment raises the level of com-
plexity even further but also increases uncertainty. Tis-
sue damage—smooth muscle cell apoptosis or necrosis
as well as local ischemia—is believed to favor calcifica-
tion. However, such tissues usually are locally acidotic. I
am not aware of many conditions in which tissue damage
occurs during alkalosis.
DR. DRU¨EKE: In many of the studies you discussed,
PTH was not identified as a factor that increases the
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extent of calcifications. On the other hand, we know from
a large number of observations that severe hyperparathy-
roidism promotes soft tissue and vascular calcification.
Do you think that in recent years people have achieved
better control of hyperparathyroidism so that PTH is not
as numerically important as in the past?
DR. FLOEGE: In most cases of secondary hyperparathy-
roidism, serum calcium does not increase, whereas its
level does rise in severe tertiary hyperparathyroidism.
Therefore, serum calcium remains normal over a very
wide range of serum PTH levels. If hypercalcemia is the
relevant pathogenetic mechanism, this lack of a linear re-
lationship between PTH and calcium levels probably ex-
plains why calcium or the calcium × phosphate product,
but usually not PTH levels, correlates with the presence
of calcification.
DR. DRU¨EKE: I think that phosphate is probably as
important as calcium because very severe hyperparathy-
roidism is generally accompanied by very high phosphate
levels.
DR. FLOEGE: I agree. In fact, phosphate is probably
even more important than calcium. In the study by Block
et al [46], phosphate levels were usually much stronger
predictors of mortality than were calcium levels. Again,
however, this relationship might reflect a dampening of a
statistical correlation; we do not determine on a routine
basis the right parameter, namely, ionized calcium. Uti-
lization of total serum calcium measurements clearly will
weaken any correlation.
DR. DAVID GOLDSMITH (Consultant Nephrologist,
Guy’s Hospital, London, United Kingdom): The impli-
cations of vascular calcification depend on where the cal-
cification is localized within the vessel wall. You showed
us that the risk factors for intimal and medial calcification
are quite different. Lipids, for example, are clearly asso-
ciated with the progression of atherosclerosis, but not, as
far as anybody knows, with the progression of medias-
clerosis. One of our problems is that we have a lot of in-
formation on the quantification of calcification but much
less on where it is in the vessel wall. How can we resolve
that?
DR. FLOEGE: The best methods we currently have for
quantification of vascular calcification, namely, electron-
beam computer scan (EBCT) and spiral CT, tell us
whether calcification is present; they do not tell us where
it is present within the vessel wall. One of the few, albeit
crude, approaches for investigating this issue is analy-
sis of plain radiographs, that is, determining whether the
pattern reflects patchy atherosclerotic or tram-track-like
medial calcifications. However, even this crude approach
becomes difficult if both types of calcification co-exist.
The techniques that most likely will be helpful in this
context are intravascular ultrasound and optical coher-
ence tomography. For example, we are involved in a re-
search project in which our colleagues in the engineering
department of the Aachen University are attempting to
improve optical coherence tomography to a resolution
level that essentially will allow in vivo microscopy of any
biologic surface including skin, mucosa, or vessel walls.
Availability of such a technique in dialysis patients would
be a major advance in our understanding of extraosseous
calcification.
DR. STEFAN HEIDENREICH (Associate Professor of
Nephrology, University Hospital, Mu¨nster, Germany):
What cells of the liver produce fetuin-A and what reg-
ulators of its production are known?
DR. FLOEGE: As far as we know, fetuin-A is mostly
produced by hepatocytes. As to regulators of its synthesis,
I have already mentioned corticosteroids but there must
be others. The promoter of fetuin-A was recently cloned
and this should quickly advance our understanding of
regulatory factors.
DR. HARRINGTON: Has calcification of the native kid-
neys been invoked as one of the factors giving rise to renal
neoplasias in dialysis patients?
DR. FLOEGE: I cannot think of a direct mode by which
intrarenal calcification might contribute to the sequence
of persistent mitogenic stimulation of tubular epithelium
that results in cyst formation, subsequent adenomatous
transformation and, finally, carcinogenesis. Also, I am
not aware of studies investigating at the histologic level
whether carcinomas in acquired renal cystic disease are
spatially related to calcification.
DR. CATHY SHANAHAN (British Heart Foundation
Lecturer, University of Cambridge, United Kingdom):
Have you looked at fetuin-A levels in other chronic in-
flammatory diseases associated or not associated with
calcification?
DR. FLOEGE: We have not studied this on a system-
atic basis. We do have controls, of course, for exam-
ple, patients with sepsis, who exhibit exceedingly low
fetuin-A levels, but this is a short-term situation with
no development of calcification. We are just starting
a study in patients with rheumatoid arthritis to deter-
mine how their fetuin-A levels relate to calcification
and mortality. These patients are obvious candidates for
such a study given their increased cardiovascular risk
and the fact that they do not suffer from hyperphos-
phatemia. On the other hand, such patients often re-
ceive vitamin D and other anti-osteoporotic therapy, so
calcifications in these patients will be multifactorial in
origin.
DR. DRU¨EKE: In the Goodman study [27], an increase
in calcification was demonstrated by EBCT only in ado-
lescents. Do you think this is just because of the limita-
tions of the method? I also would like to draw attention
to a study by Milliner et al [3], which showed tremen-
dous calcifications in uremic children much younger than
age 20. She also showed in this post-mortem study that
the most important contributory factor was vitamin D,
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not calcium or phosphate. Thus, we have more in vivo
evidence for the role of vitamin D.
DR. FLOEGE: I can only speculate that in the Goodman
study no calcifications were detected in children because
they usually receive a transplant relatively quickly. So
one of the confounding factors might be the duration of
dialysis; a second one is obviously the resolution of EBCT.
DR. GERARD LONDON (Director, Nephrology Depart-
ment, Manhes Hospital, Paris, France): I posed the same
question to Bill Goodman, and his answer exactly con-
firmed your interpretation, that is, the absence of cal-
cifications in these children was due to the short time
between dialysis and transplantation.
DR. FLOEGE: In this context I therefore believe that
the Milliner study [3] is of particular importance because
it clearly pointed out that children are not spared from
this complication as opposed to other consequences of
long-term dialysis, such as dialysis-related amyloidosis,
which has never been observed in children.
DR. DRU¨EKE: You showed the surgical approach in
one of your patients with tumor-like calcinosis (Fig. 5)
and reported that the tumor was largely solid. In our ex-
perience, such calcifications are mostly liquid and when
you open them, a kind of liquid magma flows out. Also our
experience has taught us that one should avoid surgery
in patients with large calcifications as much as possible
because these lesions often become infected.
DR. FLOEGE: You raise two important points. The pa-
tient shown in Figure 5 might be unusual, because large
solid areas were found in the tumor, but there also were
some liquid parts. Maybe, and I am speculating here, liq-
uid areas represent early stages of precipitation, that is,
amorphous calcium phosphate, and these areas subse-
quently evolve into more crystalline, solid tumors. As to
your second point, I fully agree, and I definitely do not ad-
vocate surgery in such patients. In fact, we refused surgery
in a man with tumorous calcinosis that measured about
20 cm in diameter in the hip region. Instead we advised
him to wait for a renal transplant, hoping that this will
induce regression. The patient shown in Figure 5 actually
had been refused for surgery as well in two other hospi-
tals. She insisted that this tumor was disturbing her life
to a degree that she almost became suicidal. We finally
accepted her with great hesitation. Fortunately, no com-
plications occurred after the surgery, but, again, this is
clearly the exceptional approach.
DR. KETTELER: What is your opinion on the role of
calcimimetics, new calcium binders, and vitamin D ana-
logues in the prevention of calcification?
DR. FLOEGE: The evidence, based on the “treat-to-
goal” study [38], is good in the case of calcium-free phos-
phate binders. Limitations of this study include (1) the
fact that vitamin D therapy was significantly different in
the two groups of patients, (2) the lack of data on acid-
base status in that study, which is important given that
sevelamer will induce systemic acidosis through bicar-
bonate loss, and (3) its non-blinded nature. Despite these
limitations, it is the only one that can serve for evidence-
based recommendations. As far as calcimimetics are
concerned, we do not know their role yet. There is a the-
oretical basis on which we can advocate their use for the
prevention of calcification, namely, their ability to lower
the calcium × phosphate product. Whether the effect of
calcimimetics on PTH is also important in this context
must remain open. Finally, in the case of vitamin D ana-
logues, again, we lack data. As Tilman Dru¨eke pointed
out in his New England Journal of Medicine editorial
[89], even the major recent studies comparing two vita-
min D forms suffer from problems that render a head-to-
head comparison of different vitamin D analogues almost
impossible.
DR. HARRINGTON: I’ve always been reluctant to ac-
cept data that demonstrate gene products such as bone
proteins in unexpected locations. What were the controls
in those studies?
DR. FLOEGE: In the studies on this issue, mostly those
by Sharon Moe’s group [13], the usual histochemical
controls were of course included, but probably the best
evidence for the validity of those findings is the com-
plete absence of bone-related proteins in non-calcified
arteries.
DR. SHANAHAN: I agree. In our own studies in non-
uremic, calcified vessels with diabetic or atherosclerotic
injury, the expression of bone-related proteins also was
strictly confined to calcified vessels and was never present
in non-calcified arteries [72].
DR. LONDON: You mentioned that oxidized LDL could
play a role in the induction of vascular calcification. Do
we have any data on the effect of statins on intimal calci-
fications in dialysis patients?
DR. FLOEGE: In contrast to non-ESRD patients, in
whom statins clearly prevent the induction or progress
of vascular calcifications [57], we have no such data in
ESRD patients yet. The 4D- and CHORUS trials might
provide an indirect answer in ESRD patients, as car-
diovascular events are the primary end points of both
studies. But these investigations don’t specifically address
cardiovascular calcification in uremic diabetics. Given
that the “treat-to-goal” study [38] also raised the question
of whether the phosphate and/or lipid-lowering activity
of sevelamer accounts for its beneficial effect on cardio-
vascular calcifications, we are clearly in need of studies
specifically addressing this question.
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